Table 1.
Alterations | Observation/proposed mechanism of action | Reference |
---|---|---|
Activating mutation of CARD11 in GC B cells | Rapid terminal differentiation of B cells | (26) |
Inhibition of c-Myc | Prevent DZ re-entry | (27) |
c-Rel deletion in GC B cells | Failure in metabolic program directing cell growth | (28) |
Bam 32 deficiency in GC B cells | Reduced Tfh recruitment and increased GC B apoptosis | (29) |
FDC ablation/absence of FDC | Increased GC B cell apoptosis | (30, 31) |
BAFF deficiency | Defect in FDC development and immune complex trapping | (32) |
BAFF-R deficiency | Defect in B cell proliferation | (32) |
Cr2 deficient mice | Reduced long-term antigen retention | (16) |
Absence of T cells | Apoptosis and loss of proliferating cells | (33) |
Absence of IL-21 or IL-21 receptor | Reduced GC B cell proliferation | (34) |
Absence of Tfh αv integrins | Defect in Tfh accumulation at late stages | (35) |
Absence of PD-1 | Increased GC B cell apoptosis and reduced cytokine production from Tfh | (36) |
anti-CD40L administration | Increased GC B cell apoptosis | (37) |
Constitutive CD40 signaling | Early terminal differentiation | (38) |
DZ, dark zone; Tfh, T follicular helper cells; GC, Germinal Centres; FDC, Follicular Dendritic Cells; BAFF, B cell activating factor.